Výsledky vyhledávání - "Exatecan mesylate"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Topoisomerase Inhibitors as Antibody–Drug Conjugate (ADC) Payloads

Autor: Thomas M. Cardillo, Serengulam V. Govindan, David M. Goldenberg

Publikováno v: Cytotoxic Payloads for Antibody – Drug Conjugates ISBN: 9781788010771

Topoisomerase inhibitors represent a novel class of compounds that have been used as stand-alone anticancer agents, and their incorporation into antibody conjugates adds a targeting element to the development of more selective chemotherapy. Topoisome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21ae93030f00f57811700a1634e30ddd
https://doi.org/10.1039/9781788012898-00166

Zobrazit plný text záznamu

Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology

Autor: Masataka Oitate, Toshinori Agatsuma, Koji Morita, Takeshi Masuda, Mayumi Goto, Takashi Nakada, Yuki Abe, Michiko Kitamura, Hideo Yukinaga, Junko Yamaguchi, Takuma Iguchi, Tomoko Terauchi, Yusuke Ogitani, Koichi Goto, Yoshiyuki Yabe

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 26:5069-5072

To establish a novel and widely applicable payload-linker technology for antibody-drug conjugates (ADCs), we have focused our research on applying exatecan mesylate (DX-8951f), a potent topoisomerase I inhibitor, which exhibits extensive antitumor ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6eee2176b9616125834aac7a817f179
https://doi.org/10.1016/j.bmcl.2016.08.082

Zobrazit plný text záznamu

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

Autor: Makio Kamida, Luis Baez, Carlos Becerra, Alejandro Silva, Chris H. Takimoto, Pierre Major, Jaffer A. Ajani, Robert De Jager, Allen Cohn, Kevie Feit

Publikováno v: Investigational New Drugs. 23:479-484

Purpose: To determine the anti-tumor activity DX-8951f when administered as a 30-minute infusion daily for 5 days every 3 weeks to patients with previously untreated metastatic gastric cancer, and to evaluate toxicities and pharmacokinetics (PK) of D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a8f2bfeeb158e11e5f0cfbf576a9fa
https://doi.org/10.1007/s10637-005-2907-z

Zobrazit plný text záznamu

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity

Autor: I J Hoogsteen, Marc Maliepaard, Epie Boven, R.J. Scheper, Hennie M.M. Schlüper, A. H. Van Hattum, G Kohlhagen, George L. Scheffer, H.M. Pinedo, Y Pommier

Publikováno v: British Journal of Cancer

DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the hu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bba8bb70344f94c01c5eeb71130aeed
https://doi.org/10.1038/sj.bjc.6600508

Zobrazit plný text záznamu

Gynaecological cancer

Autor: Cheverton, Vasey, Ganesan, Atkinson, Jayson, Adams, Cervantes-Ruiperez, Calvert, Boven

Publikováno v: Annals of Oncology. 11:81-90

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd60391395462a3a72ec5e1c0f739a3f
https://doi.org/10.1093/annonc/11.suppl_4.81

Zobrazit plný text záznamu

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

Autor: Eiji Kumazawa, Akiko Tohgo, Takeshi Jimbo, Yusuke Ochi

Publikováno v: Cancer Chemotherapy and Pharmacology. 42:210-220

Purpose: We have previously reported that DX-8951f, a water-soluble and nonprodrug camptothecin (CPT) derivative, exhibits both high in vitro potency against a series of 32 malignant cell lines and significant topoisomerase I inhibition. The purpose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c3288dfa40998a5eff937e2af45b58
https://doi.org/10.1007/s002800050807

Zobrazit plný text záznamu

A New Water-soluble Camptothecin Derivative, DX-8951f, Exhibits Potent Antitumor Activity against Human Tumorsin vitroandin vivo

Autor: Masamichi Sugimori, Satoru Ohsuki, Yasuhide Hirota, Eiji Kumazawa, Masashi Aonuma, Kouichi Uoto, Hirofumi Terasawa, Akio Ejima, Ikuo Mitsui, Keiki Sato

Publikováno v: Japanese Journal of Cancer Research : Gann

CPT‐11, a semisynthetic derivative of camptothecin, exhibited strong antitumor activity against lymphoma, lung cancer, colorectal cancer, gastric cancer, ovarian cancer, and cervical cancer. CPT‐11 is a pro‐drug that is converted to an active m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0deebf591f2521e13b34c6191e4d7992
https://doi.org/10.1111/j.1349-7006.1995.tb02468.x

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Current Status of Camptothecin Analogues as Antitumor Agents

Autor: William Slichenmyer, Eric K. Rowinsky, Scott H. Kaufmann, Ross C. Donehower

Publikováno v: JNCI Journal of the National Cancer Institute. 85:271-291

The nuclear enzyme topoisomerase I (topo I) has been recently recognized as the target for the anticancer drug camptothecin (CPT) and its derivatives. Two of the agents that target this enzyme--topotecan (TPT) and CPT-11--appear to be active against

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a5b0d359cb5f1629fbc582011568943
https://doi.org/10.1093/jnci/85.4.271

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání